Expanding the Role of Pharmacists in Non-Statin LDL-C Therapy Utilization

This episode, titled Expanding the Role of Pharmacists in Non-Statin LDL-C Therapy Utilization, features cardiology experts discussing the following critical questions:

Do you believe that the non-statin LDL-C lowering therapies are currently underutilized?

If yes, how can pharmacists play a bigger role in ensuring that more patients are being prescribed these therapies?

What additional clinical data would you like to see with non-statin LDL-C lowering therapies in the future?

Led by the moderator, the experts examined non-statin LDL-C–lowering therapies, which are widely considered underutilized, often due to limited awareness, cost barriers, and clinical inertia. Pharmacists can play a larger role by identifying eligible patients, facilitating prior authorizations, educating both patients and providers, and supporting adherence monitoring. Expanding pharmacist involvement in multidisciplinary care can help ensure more patients receive these therapies when clinically indicated. Future clinical data that would be valuable include long-term cardiovascular outcomes, comparative effectiveness with existing therapies, and real-world safety and adherence profiles across diverse patient populations.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.In the next episode, The Evolving Role of Pharmacists in Cardiovascular Disease Management: Insights and Future Perspectives, panelists will close out their discussion on the role of the pharmacist in cardiovascular disease management, which is likely to expand from dispensing and counseling to actively leading medication management, adherence monitoring, and patient education. Pharmacists will also play a key role in guiding therapy selection, supporting access to novel treatments, and collaborating closely with the healthcare team to optimize long-term cardiovascular outcomes.